Loading...
Loading...
Nasus Pharma Ltd
Nasus Pharma Ltd. Spoken Alpha tracks NSRX's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks NSRX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 70% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NSRX.
curl https://api.spokenalpha.com/v1/companies/NSRX| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.42 | $3.31 | +33.4% | -2.5% | -2.5% |
| Q4 FY2026 | $4.07 | $3.16 | +28.8% | -1.5% | -3.5% |
| Q3 FY2026 | $4.50 | $3.32 | +35.4% | +0.4% | +0.2% |
| Q2 FY2026 | $4.24 | $3.40 | +24.7% | +0.6% | +3.5% |
| Q1 FY2025 | $4.29 | $3.40 | +26.2% | -1.2% | -2.6% |
| Q4 FY2025 | $4.57 | $3.42 | +33.6% | +3.6% | +2.0% |
| Q3 FY2025 | $4.07 | $3.26 | +24.7% | +6.9% | +5.7% |
| Q2 FY2025 | $4.66 | $3.44 | +35.6% | +0.3% | +2.1% |
| Q1 FY2024 | $4.20 | $3.23 | +30.0% | +5.2% | +4.8% |
| Q4 FY2024 | $4.48 | $3.51 | +27.6% | +4.9% | +6.6% |